Behavioural evaluation of cholinergic drugs

Area of Science:

• Neuroscience
• Pharmacology
• Drug Discovery

Background:

• Alzheimer's disease (AD) is characterized by progressive neurodegeneration in the cortex and limbic system.
• A key feature of AD is the loss of forebrain neurochemical systems, particularly the basal forebrain cholinergic system.
• Current therapeutic strategies focus on enhancing forebrain muscarinic receptor function.

Purpose of the Study:

• To evaluate novel muscarinic agonists with functional selectivity for M1/M3 receptors in the central nervous system (CNS) and M2 antagonism.
• To assess the efficacy of these compounds in reversing cognitive deficits in animal models of memory impairment.
• To compare the efficacy of these novel agonists with existing acetylcholinesterase inhibitors.

Main Methods:

• Development of muscarinic agonists with selective M1/M3 agonism and M2 antagonism.
• Administration of these compounds to rodent and monkey models exhibiting scopolamine-induced cognitive impairment.
• Assessment of reference and working memory performance in treated animal models.

Main Results:

• The developed muscarinic agonists demonstrated functional selectivity for M1/M3 receptors in the CNS, with M2 antagonist properties.
• These compounds effectively reversed cognitive impairments in both rodent and monkey models.
• Acetylcholinesterase inhibitors showed even greater efficacy in the tested memory models.

Conclusions:

• Selective M1/M3 muscarinic agonists with M2 antagonist properties represent a promising therapeutic avenue for Alzheimer's disease.
• These compounds offer a potential reduction in cardiac and other cholinergic side effects compared to non-selective agents.
• While effective, acetylcholinesterase inhibitors remain a benchmark for cognitive enhancement in Alzheimer's models.